Management of Elevated Hematocrit in Patients on Clopidogrel Post-Stent

Immediate Clinical Assessment

The American Heart Association recommends assessing thrombotic risk factors urgently, as stent thrombosis presents as STEMI in most cases and survivors remain at high risk for recurrent thrombosis 1
The American College of Cardiology suggests determining time since stent placement, as the highest risk period is within the first 30 days, with ongoing risk of 0.2-0.6% per year thereafter 1
Verify clopidogrel adherence, as nonadherence to dual antiplatelet therapy (DAPT) is the most common cause of acute stent thrombosis 1, 2

Review medication list, as testosterone replacement, anabolic steroids, and erythropoietin-stimulating agents can elevate hematocrit 3
Order JAK2 V617F mutation testing if secondary causes are excluded, as this is present in >95% of polycythemia vera cases 2
Measure erythropoietin level, as low or inappropriately normal levels suggest primary polycythemia vera 4

Continue clopidogrel 75mg daily without interruption, as discontinuation dramatically increases stent thrombosis risk 1, 2
Verify aspirin continuation at 75-100mg daily, as DAPT is essential for stent protection 4, 3
Consider therapeutic phlebotomy if hematocrit >54% to reduce hyperviscosity and thrombotic risk while awaiting definitive diagnosis 3

Assess for symptoms of myocardial ischemia, including chest pain, dyspnea, or anginal equivalents that could indicate inadequate platelet inhibition 1
Maintain DAPT duration based on stent type, with a minimum of 12 months for drug-eluting stents and minimum 1 month (ideally up to 12 months) for bare-metal stents 4, 3, 5

Never discontinue clopidogrel abruptly without cardiology consultation, as this is the leading cause of stent thrombosis with devastating consequences 1, 2
Avoid overlooking secondary causes of polycythemia before pursuing expensive workup for primary disorders 4
Do not delay phlebotomy if hematocrit remains significantly elevated, as hyperviscosity compounds the already elevated thrombotic risk from coronary disease and stenting 3